Abstract: A method for converting cedarwood oil into high density fuels including, hydrogenating cedarwood oil in the presence of at least one hydrogenation catalyst to generate hydrogenated cedarwood oil, removing the hydrogenation catalyst from the hydrogenated cedarwood oil, purifying the hydrogenated cedarwood oil to produce a first high density fuel, isomerizing the first high density fuel in the presence of at least one acid catalyst catalyst to generate a hydrocarbon mixture including adamantanes, and distilling the adamantane mixture to produce a second alkyl-adamantane high density fuel.

Abstract: A method to generate dense, multi-cyclic diamondoid fuels from bio-derived sesquiterpenes. This process can be conducted with both heterogeneous and homogenous catalysts and produces the targeted isomers in high yield. The resulting multi-cyclic structures impart significantly higher densities and volumetric net heats of combustion while maintaining low viscosities which allow for use at low temperature/high altitude. Moreover, bio-derived sesquiterpenes can be produced from renewable biomass sources. Use of these fuels will decrease Navy dependence on fossil fuels and will also reduce net carbon emissions.

Abstract: The invention relates to bacterium that have increased resistance to furfural and methods of preparation. The invention also relates to methods of producing ethanol using the bacterium and corresponding kits.

Abstract: The present invention relates to Saccharomyces cerevisiae strains suitable for the production of baker's yeasts which are osmotolerant and which exhibit intrinsic resistance to weak organic acids. The strains of the present invention are obtained by means of a process of hybridization or of mutation of the industrial S. cerevisiae strain deposited on Jul. 8, 2010 with the CNCM [French National Collection of Microorganism Cultures] under number I-4341, or from an industrial strain related thereto via the Ty profile thereof and/or via quantitative trait locus mapping (QTL mapping).

Abstract: Using a whole-cell high-throughput screen, eleven molecules were identified that activate V. cholerae quorum sensing (QS). Eight molecules are receptor agonists and three molecules are antagonists of LuxO, the central NtrC-type response regulator that controls the global V. cholerae QS cascade. Pro-QS molecules are used for the development of novel anti-infectives.

Abstract: The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.

Abstract: Processes are provided for starting up of anaerobic, deep tank fermentation systems used in the anaerobic bioconversion of hydrogen and carbon monoxide in a gaseous substrate stream to oxygenated organic compounds such as ethanol. In the processes injectors using a motive liquid are used to introduce gas substrate into the deep tank fermentation reactor where at least one of: (i) adjusting the gas to liquid flow ratio through an injector, (ii) changing the rate of liquid flow through an injector, and (iii) adjusting the carbon monoxide mole fraction in the gas feed by admixture with at least one other gas, wherein the mass transfer of carbon monoxide to an aqueous menstruum in the reactor is controlled to obtain the robust growth of the microorganism while maintaining the carbon monoxide concentration below that amount which is unduly adverse to the microorganism.

Abstract: Provided herein are processes for producing an improved culture of cells comprising an engineered butanol biosynthetic pathway. The processes comprise (a) providing a cell culture of recombinant microorganisms comprising an engineered butanol biosynthetic pathway, wherein the engineered butanol biosynthetic pathway is minimal or not activated; and (b) growing the culture of recombinant microorganisms under adaptive conditions whereby pathway activation is increased to produce an improved cell culture and whereby said improved cell culture is capable of continuing to grow in fermentation.

Abstract: Disclosed herein are methods and compositions to convert a carbonaceous material to produce a fatty acid, biofuel, biodiesel, or other useful end-product. Organisms are evolutionarily modified to utilize carbon and/or nitrogen sources available in a carbonaceous material. Culture of the evolutionarily modified organism on the carbonaceous material in turn produces a fatty acid, biofuel, biodiesel, or other useful end-product by a process of conversion performed by evolutionarily modified organisms.

Abstract: The present invention relates to a method for improving viability and/or stress tolerance of viable biological material and using the said material comprising applying hydrostatic pressure to said biological material; keeping the said viable biological material at the hydrostatic pressure for a predetermined time period; releasing the hydrostatic pressure; and using the said material for any desired purpose in accordance with any useful protocol. The usage of the said biological material incorporates any techniques, protocols that are applicable in the field of assisted reproductive techniques, biotechnical and/or biotechnological manipulations.

Abstract: Compounds that affect quorum sensing (QS) in Staphylococcus aureus and related Staphylococcus species (e.g., S. epidermidis). Compounds which modulate one or more of the four AgrC receptors of Staphylococcus species, particularly of Staphylococcus aureus. Modulation includes inhibition or activation of one or more of these four AgrC receptors. These compounds are useful for bacterial interference and are useful for treating bacterial infections, particularly staphylococcal infection. Treatment can include combination of one or more of the compounds of the invention in combination with one or more antibiotics.

Abstract: Disclosed herein is a novel antifungal compound, derivatives that are used to treat fungal infections. In a specific embodiment, the compound is a small molecule. In a specific embodiment, the compound described herein inhibits yeast to hypha transition under robust hyphal inducing conditions at lower concentration of the molecule. Also disclosed is a composition comprising the antifungal compound. In a specific embodiment, the composition is a pharmaceutical composition. Also disclosed is a method of treating and/or preventing fungal infection using the disclosed compound. The disclosed compound exhibits antifungal activity against wide range of fungal species at slightly higher concentrations. Antifungal compound disclosed herein is used as anti-biofilm agent against fungal infections.

Abstract: This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances.

Abstract: By administering sterilized bacterial cells obtained by heat treating cells of a coryneform bacterium or an enterobacterium under a condition of pH 2 to 5 at 90 to 120° C. for 3 minutes to 4 hours, or a feed containing such sterilized bacterial cells to a mammal, fowl, fish, or crustacean, immunity of these animals is enhanced.

Abstract: The present invention relates to processes for the production of microalgae, cyanobacteria and/or metabolites thereof. Described herein is a process involving, the use of a stimulus applied to a microalgal or cyanobacterial culture to enhance the production of one or more metabolites. Also described herein, is a process for the production of microalgae and/or cyanobacteria comprising an adaptation stage wherein an algaltcyanobacterial culture is grown on a process water feedstock and/or under light emitting diodes (LEDs) emitting light within the spectrum of light wavelengths between around 400 nm and 700 nm, and a production phase, wherein the microalgae or cyanobacteria are grown on the same process water feedstock and/or under the same light conditions used in the adaptation stage. The invention also relates to specific microalgal strains.

Abstract: It is intended to exert a higher control effect on plant-pathogenic fungi. The mycovirus of the present invention has 5 types of double-stranded RNAs, wherein 4 types of double-stranded RNAs out of the 5 types of double-stranded RNAs have 81%, 75%, 72%, and 73% or higher homologies to the nucleotide sequences represented by SEQ ID NOs: 1 to 4, respectively. As an example, a novel mycovirus MoCV3 is used.

Abstract: A process for the culture of Leptospires in a protein-free culture medium and without any fatty acid source in the culture medium, wherein a fatty acid source is fed continuously or intermittently.

Abstract: Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.

Abstract: A yeast of the genus Kluyveromyces is modified to improve the ethanol yield from xylose by attenuation of at least one gene selected from the group consisting of the ADH1 gene derived from Kluyveromyces marxianus, a gene functionally equivalent to the ADH1 gene, the ADH4 gene derived from Kluyveromyces marxianus, and a gene functionally equivalent to the ADH4 gene.

Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.

Abstract: A cis- or trans-stilbenoid of the general formula (1): in which each of R1, R2, R3, R4 and R5 is hydrogen or hydroxy, or a glycosylated or oligomeric form thereof, is produced by cultivating a micro-organism producing said stilbenoid, in a multi-phase system comprising at least an aqueous first phase containing said micro-organism and a second phase immiscible with said aqueous phase in which (e.g. as which) said stilbenoid accumulates. The second phase may be said stilbenoid or a free or encapsulated solvent compatible with the growth of the micro-organism, for instance an ester.

Abstract: The present invention relates to a mutated Francisella bacterium, wherein the ggt gene is silenced or deleted; pharmaceutical compositions comprising the same, in particular, vaccine compositions, and use of the bacterium and compositions for treatment and/or prophylaxis, and in particular, the treatment or prophylaxis of tularemia.

Abstract: Described are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue), the resulting (high purity) compounds, compositions comprising such compounds (e.g., tablets, capsules), and the use of such high purity compounds. The compounds are useful in inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis of diseases including a tauopathy, related neurological and infectious diseases.

Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.

Abstract: An object of the present invention is to provide a microorganism which is novel at the elemental composition level, and to provide a technique for providing such a microorganism. The present inventor has succeeded in causing a microorganism to efficiently contain a non-essential element by decreasing the content of an essential nutrient source for the microorganism, a C source, an N source, a P source, or an S source, and by adding an X compound containing the non-essential element as a constitutive element in a manner to make up for the decreased amount, and then culturing the microorganism.

Abstract: Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

Abstract: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM 1-2618) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: The present invention provides live recombinant microorganisms such as prokaryote organisms, particularly enterobacteria, preferably Salmonella enterica, containing SEQ. ID. no. 1 and SEQ. ID. no. 2 capable of expressing VapG and/or VapA/VapG lipoproteins (SEQ. ID. no. 3 and SEQ. ID. no. 4), optionally in combination with other active ingredients, methods for preparing vaccine strains, antigens (SEQ. ID. no. 3 and SEQ. ID. no. 4) and vaccine compositions, preferably vectored vaccines. Additionally, the present patent application relates to the use of the vaccine vectors in the preparation of pharmaceutical compositions, particularly vaccines indicated for the prevention and/or treatment of infections by Rhodococcus equi, its antibodies and/or antisera, diagnostic kits and methods for the prophylaxis and/or treatment of infections by R. equi.

Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.

Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.

Abstract: The present invention relates to an attenuated strain of Ehrlichia canis and a vaccine comprising said attenuated strain for protection of mammals against ehrlichiosis. The invention further relates to methods of preventing ehrlichiosis and of attenuating the pathogenicity Ehrlichia canis.

Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.

Abstract: A new microbial strain of the species Streptococcus salivarius for use in the treatment of inflammatory processes with or without infectious etiology. A further object of the present invention compositions including the strain and uses thereof.

Abstract: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.

Abstract: A synchronized water is disclosed, in which all single water molecules at the same time are arranged in an identical way to a stable homogeneous microstructure, wherein said synchronized water in a distilled condition and at atmospheric pressure has a) a density of from 0.997855 to 0.998836 g/ml at 22° C., b) a water temperature at the freezing point of from ?6.7° C. to ?8.2° C., c) a melting point of from 0.1° C. to 0.2° C., d) a surface tension of from 72.3 to 72.7 dyn/cm at 22 and e) a dielectric constant of from 82.4 to 82.6 F/m, as well as a method for preparation thereof and different uses thereof.

Abstract: The present invention relates to methods of obtaining Z. mobilis mutant strains that are more tolerant to one or more inhibitors or more capable of efficiently fermenting one or more carbohydrates. Such inhibitors include ethanol, aliphatic acids, such as acetic acid, formic acid; furan derivatives, such as 2-furaldehyde, 2-furoic acid; and phenolic compounds, such as vanillin and hydroxybenzoic acid. Such carbohydrates may include xylose, arabinose, mannose and mixtures thereof. These mutant strains may be employed to, for example, effectively and efficiently prepare ethanol from biomass.

Abstract: Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.

Abstract: The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated Listeria are mutant Listeria that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated Listeria are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.

Abstract: Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.

Abstract: Novel strains and methods for their use are provided. Particularly, foods and other oral products or treatments containing sporulation-deficient Brevibacillus strain when administered to a subject can inhibit or reduce the number of pathogens in the subject and improve the health of the subject.

Abstract: The present invention relates to methods for producing Saccharomyces strains that are capable of growth on xylose as a sole carbon source at a desired growth rate, (such as at least one generation per 48 hours), strains made by such methods, and Saccharomyces strains that grow at a growth rate of at least one generation per 48 hours using xylose as a sole carbon source for growth made by non-recombinant methods.

Abstract: The present invention discloses a vaccine that provides protection to turkeys from coccidiosis, and methods of making and using the vaccine alone, or in combinations with other protective agents. In addition, the present invention discloses PCR primer sets that are useful in identifying the species of Eimeria in a biological sample.

Abstract: Strains of xylose utilizing Zymomonas with improved xylose utilization and ethanol production during fermentation in stress conditions were obtained using an adaptation method. The adaptation involved continuously growing xylose utilizing Zymomonas in media containing high sugars, acetic acid, ammonia, and ethanol.

Abstract: Live attenuated bacteria vaccines are provided. Also provided are methods by which such vaccines can be obtained, including: a method by which a copy of the dam gene from a pathogenic bacteria is cloned into a plasmid capable of replication in the same bacteria species such that it is overexpressed from either a lac promoter, tac promoter, araBAD promoter, trc promoter, trp promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter. The plasmid containing the dam gene is then transferred into the pathogens to cause increased expression of Dam resulting in the formation of a live attenuated bacterial vaccines. Alternative methods for producing the vaccine are also provided including altering or replacing the chromosomal promoter for the native dam gene so as to alter Dam expression or mutating or replacing the native dam gene so as to alter the expression of Dam in a pathogenic bacteria.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM I-2618) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: Equipment for treating wastewater by anaerobic ammonium oxidation includes an anaerobic ammonium oxidation vessel to receive water to be treated containing ammonium and nitrite and to denitrify ammonium and nitrite in the water by anaerobic ammonium oxidizing bacteria, forming denitrified treated water, an acclimatization vessel downstream from the anaerobic ammonium oxidation vessel to receive the denitrified treated water from the anaerobic ammonium oxidation vessel, the acclimization vessel containing an immobilizing material that collects the anaerobic ammonium oxidizing bacteria in the denitrified treated water as immobilized microorganisms attached to the immobilizing material, wherein the acclimatization vessel has a structure such that the immobilizing material is prevented from flowing out of the acclimatization vessel, and a pipe connecting the acclimatization vessel to the anaerobic ammonium oxidation vessel.

Abstract: The present invention relates to a mutated Francisella bacterium, wherein the ggt gene is silenced or deleted; pharmaceutical compositions comprising the same, in particular, vaccine compositions, and use of the bacterium and compositions for treatment and/or prophylaxis, and in particular, the treatment or prophylaxis of tularemia.

Abstract: The present invention concerns a new method for the production of 1,3-propanediol comprising culturing a microorganism on a culture medium with high glycerine content. The invention also concerns a new microorganism, or strain of microorganism, adapted for the production of 1,3-propanediol from medium comprising high glycerine content. The invention also concerns an “adapted microorganism” which glycerol metabolism is directed to 1,3-propanediol production, and which is allowed to grow in the presence of a high concentration of industrial glycerine. The invention also concerns a biosourced 1,3-propanediol obtained by the process thereof. Finally the invention concerns the use of the above described biosourced 1,3-propanediol as extender chain in thermoplastic polyurethane, as monomers in polytrimethylene terephtalate and as a component in cosmetics formulations.